Aurinia Pharmaceuticals Inc. AUPH shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales figures.
What to Know: On Tuesday, Aurinia reported its full-year and fourth-quarter sales and earnings figures for the period that ended Dec. 31, 2022. The company also reaffirmed its full-year 2023 guidance.
The company announced a fourth-quarter loss of $0.18 per share compared to analyst estimates for a loss of $0.27 per share, representing a positive earnings surprise of 33.3%. Aurinia reported fourth-quarter sales of $28.43 million beating analyst estimates of $27.78 million.
Aurinia reported full-year 2022 revenues of $134 million, compared to $45.6 million in 2021.
Aurinia also provided guidance for 2023. The company expects double-digit revenue growth compared to 2022. Aurinia sees revenues from its drug, LUPKYNIS in the range of $120 million-$140 million.
"As an organization, we continue to advocate for improved screening, diagnosis and the treatment of lupus nephritis with healthcare providers while reinforcing the clinical benefits of LUPKYNIS over the historic standard of care," said Peter Greenleaf, president and CEO of Aurini a Pharmaceuticals.
See Also: Why Cardio Diagnostics Stock is Soaring Today
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by autoimmune, kidney and rare diseases with a high unmet medical need.
According to data from Benzinga Pro, Aurinia Pharmaceuticals shares were up 9.66%, trading at $9.14 at the time of publication. The stock has a 52-week high of $16.30 and a 52-week low of $4.07.
Photo: courtesy of Aurinia.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.